No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BDX240621P180000
- 0.05
- 0.000.00%
15min DelayTrading May 20 11:30 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume2 Open Interest180.00Strike Price0.00Turnover67.17%IV23.35%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0059Delta0.0007Gamma4695.10Leverage Ratio-0.0195Theta-0.0003Rho-27.83Eff Leverage0.0063Vega
Intraday
- 5D
- 1D
News
Wells Fargo Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $290
Wells Fargo analyst Larry Biegelsen maintains $Becton Dickinson & Co(BDX.US)$ with a buy rating, and maintains the target price at $290.According to TipRanks data, the analyst has a success rate of 60
Becton Dickinson & Co(BDX.US) Officer Sells US$71,793 in Common Stock
$Becton Dickinson & Co(BDX.US)$ Officer Spoerel Thomas J sold 300 shares of common stock on Jun 10, 2024 at an average price of $239.31 for a total value of $71,793.Source: Announcement What is statem
Peering Into Becton Dickinson's Recent Short Interest
Becton Dickinson's (NYSE:BDX) short percent of float has fallen 9.33% since its last report. The company recently reported that it has 1.97 million shares sold short, which is 0.68% of all regular sha
Becton Dickinson & Co's Dividend Analysis
Express News | NYSE Order Imbalance 57670.0 Shares on Sell Side
Morgan Stanley Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $280
Morgan Stanley analyst Patrick Wood maintains $Becton Dickinson & Co(BDX.US)$ with a buy rating, and maintains the target price at $280.According to TipRanks data, the analyst has a success rate of 61
Comments
$Becton Dickinson & Co(BDX.US$ GAME OVER stock.
Despite a dip in earnings, Becton Dickinson's high P/E ratio persists due to anticipated robust future growth, outpacing the broader market. Investors' confidence in the company's future earnings is high, indicating the share price is unlikely to drop significantly soon.
$Becton Dickinson & Co(BDX.US$ BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
2
Dr. Silverman's extensive experience and zeal for innovation, evidence generation, clinical development, medical safety, and compliance is predicted to boost BD's innovation pipeline and foster improved, personalized care.
Market sentiment towards Becton, Dickinson and Company shows no major shift in the past year. However, the rise in total shareholder return hints at a growing positivity.
Read more